Latest & greatest articles for pregabalin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregabalin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregabalin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregabalin

63. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials

Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials Hauser W, Bernardy K, Uceyler N, Sommer C CRD summary The authors concluded that there was strong evidence that gabapentin and pregabalin could reduce (...) pain, improve sleep and improve health related quality of life for patients with fibromyalgia syndrome. This was a generally well-conducted review. However, limited studies (number and quality), restricted generalisability and prevalent side effects indicate the authors' conclusion should be treated with extreme caution. Authors' objectives To assess the efficacy of gabapentin and pregabalin in the treatment of fibromyalgia syndrome. Searching MEDLINE, PsycINFO, Scopus and The Cochrane Library were

DARE.2009

64. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Quilici S, Chancellor J, Lothgren M, Simon D, Said G, Le TK, Garcia-Cebrian A, Monz B CRD summary This review concluded that duloxetine was comparable (...) in efficacy and tolerability to gabapentin and pregabalin for treatment of diabetic peripheral neuropathic pain. The cautious conclusions of this generally well-conducted review appear reliable, but were based on an indirect comparison of a small number of studies. Authors' objectives To evaluate the efficacy and tolerability of drugs for diabetic peripheral neuropathic pain (DPNP) and to perform indirect comparisons of duloxetine with pregabalin, gabapentin and amitriptyline. Searching PubMed, EMBASE

DARE.2009

65. Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder

Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Article Text Therapeutics Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article please use the link below

Evidence-Based Mental Health2008

66. A randomized controlled trial of perioperative administration of pregabalin for pain after laparoscopic hysterectomy

A randomized controlled trial of perioperative administration of pregabalin for pain after laparoscopic hysterectomy 17507163 2007 12 18 2008 03 10 2015 11 19 1872-6623 134 1-2 2008 Jan Pain Pain A randomized controlled trial of perioperative administration of pregabalin for pain after laparoscopic hysterectomy. 106-12 Pregabalin has anticonvulsant, antihyperalgesic, and anxiolytic properties. In this study we evaluated the control of pain after perioperative administration of pregabalin 300 (...) or 600 mg, compared with diazepam 10mg. Altogether 91 women scheduled for laparoscopic hysterectomy were randomized to receive diazepam 10mg (D10), pregabalin 150 mg (P300) or 300 mg (P600) for premedication, and the dose was repeated after 12h, except for the D10 group, in which the patients received placebo. Up until the 1st postoperative morning, analgesia was provided by oxycodone using patient controlled analgesia. The visual analogue scale scores for pain and side effects, and the amounts

EvidenceUpdates2008

67. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain

A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain Annemans L, Caekelbergh K, Morlion B, Hans G, De Cock P, Marbaix S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of pregabalin added to usual care, compared with usual care alone, for the treatment of peripheral neuropathic pain. The authors concluded that pregabalin led to a small, but significant, improvement in patient health without increasing costs from the perspective of the Belgian health care payer. In general, the quality

NHS Economic Evaluation Database.2008

68. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy

Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy Vera-Llonch M, Brandenburg N A, Oster G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of pregabalin as an additional therapy in comparison with usual care in patients with refractory partial epilepsy. The authors concluded that the cost-effectiveness of pregabalin compared favourably with the published estimates of the cost-effectiveness of other add-on antiepileptic drugs. The study

NHS Economic Evaluation Database.2008

69. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective

Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Liedgens H (...) and pregabalin for the treatment of patients with post-herpetic neuralgia. The authors concluded that the lidocaine plaster was the most cost-effective treatment. The methodology had several limitations, so the authors' conclusions should be treated with caution. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study objective The aim was to assess the cost-effectiveness of four options for the treatment of post-herpetic neuralgia in patients who did not experience pain

NHS Economic Evaluation Database.2008

70. Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis

Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis Hurley RW, Lesley MR, Adams MC, Brummett CM, Wu CL CRD summary The authors concluded that pregabalin significantly decreased the effects of pain associated with diabetic peripheral neuropathy in comparison to placebo. The use of systematic (...) review methodology and consistency of effects suggested that the conclusions were robust, but the generalisability of the results was unclear given the small sample sizes and reliability may be compromised by the process of study selection. Authors' objectives To compare the efficacy of pregabalin and placebo in the treatment of diabetic peripheral neuropathy (DPN). Searching PubMed and EMBASE were searched from 1966 to 2007 to identify relevant studies. References of relevant abstracts were checked

DARE.2008

71. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia

Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia Rodriguez M J, Diaz S, Vera (...) -Llonch M, Dukes E, Rejas E A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of branded pregabalin (PGB) in comparison with generic gabapentin (GBP) in patients with neuropathic pain due

NHS Economic Evaluation Database.2007

73. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective

Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian (...) ) and postherpetic neuralgia (PHN). The treatments were gabapentin (between 900 and 3,600 mg/day) and pregabalin (between 150 and 600 mg/day). In particular, the analysis focused, in the base-case, on a dosage of 2,400 mg for gabapentin and 430 mg for pregabalin. Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The study population comprised two hypothetical cohorts, one of patients with DPN and one of patients with PHN. Only patients

NHS Economic Evaluation Database.2006

75. Pregabalin (Lyrica) - Generalised anxiety disorder in adults

Pregabalin (Lyrica) - Generalised anxiety disorder in adults Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6997 Fax 0141 248 3778 E-mail rosie.murray@nhshealthquality.org Chairman Professor David Webb Scottish Medicines Consortium pregabalin (Lyrica) (No. 339/06) Pfizer Ltd Statement of Advice 10 November 2006 ADVICE: in the absence of a submission from the holder of the marketing authorisation. Pregabalin (Lyrica) is not recommended for use within NHSScotland

Scottish Medicines Consortium2006

77. High dose pregabalin is effective for the treatment of generalised anxiety disorder

High dose pregabalin is effective for the treatment of generalised anxiety disorder High dose pregabalin is effective for the treatment of generalised anxiety disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main (...) menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High dose pregabalin is effective for the treatment of generalised anxiety disorder Article Text Therapeutics High dose pregabalin is effective for the treatment of generalised anxiety disorder Free Raymond Pary , MD Statistics from Altmetric.com No Altmetric data available for this article. Feltner DE, Crockatt JG, Dubovsky SJ, et

Evidence-Based Mental Health2005

78. Pregabalin for peripheral neuropathic pain

Pregabalin for peripheral neuropathic pain Pregabalin for peripheral neuropathic pain Pregabalin for peripheral neuropathic pain Hadj Tahar A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hadj Tahar A. Pregabalin for peripheral neuropathic pain. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2005: 4 (...) Authors' objectives The aim of this report is to review the available information on the use of pregabalin (Trade Mark: Lyrica), an anticonvulsant drug, in the treatment of adults with peripheral neuropathic pain (NeP). Authors' conclusions The costs associated with pregabalin treatment may not compare favourably with that of generic gabapentin. However, gabapentin is not approved for the treatment of NeP by Health Canada. While pregabalin appears to be an effective treatment for NeP

Health Technology Assessment (HTA) Database.2005